Use this page as a reference for Propanc Biopharma's Net Income, including how it is computed and what it currently shows. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors. Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-58.92 M
The Net Income data shown for Propanc Biopharma is reference information derived from the latest available reporting period and does not constitute investment advice.
Analyzing Propanc Biopharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Propanc Biopharma's current valuation and future prospects.
Latest Propanc Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of Propanc Biopharma Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Propanc Biopharma Common financial statement analysis. It represents the amount of money remaining after all of Propanc Biopharma Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Propanc Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Propanc Biopharma's overall financial position and show how it may be relating to other accounts over time.
Projecting a fair value for Propanc Stock accurately depends on understanding the correlations between Propanc Biopharma's key financial drivers, including Net Income. Since Propanc Biopharma's financial accounts are interconnected across its income statement, balance sheet, and cash flow statement, changes in one account typically affect the others.
Year-over-year analysis suggests Accumulated Other Comprehensive Income is positioned to increase significantly. The most recent annual figure for Accumulated Other Comprehensive Income was 1.52 Million.
Propanc Biopharma's Net Income of -58.92 Million compares 117.27% below the Biotechnology sector. Relative to the Health Care industry, the figure is 184.12% below. The all United States stocks average is 110.32% above Propanc Biopharma's level.
Fundamental Drivers Relationships
Cross-company financial ratios help determine Propanc Biopharma's valuation standing. Mapping the correlation between Propanc Biopharma's fundamental drivers and peer metrics highlights which indicators are most influential for its intrinsic value. More Info.
Propanc Biopharma Common is rated fourth in net income among leading competitors. It also is rated fourth in return on asset among leading competitors . Net Loss is evolving in line with broader financial reporting trends. Year-ago financials show Propanc Biopharma with Net Loss of -53.03 Million. Earnings-based multiples benchmark Propanc Biopharma's market valuation.
Net Income Peer Comparison
Comparing Propanc Biopharma to its peers on Net Income is a standard technique for assessing relative investment value. Investors use this approach to identify whether Propanc Biopharma's Net Income is better or worse than comparable stocks and to uncover undervalued alternatives.
Propanc Biopharma is currently under evaluation in net income among leading competitors.
Propanc Biopharma Current Valuation Drivers
Key valuation metrics for Propanc Biopharma are extracted from the analysis of Propanc Biopharma's financial statements across multiple reporting periods. These indicators assess how efficiently Propanc Biopharma's generates profit relative to its revenue, operational costs, and shareholder equity.
Propanc Biopharma reports ROE of -18.12%. Propanc Biopharma's operating framework provides insight into margin behavior and earnings persistence. Cash-flow generation trends help validate reported earnings quality. For this reporting period, Propanc Biopharma reflects positive EPS of 52.11.
For Propanc Biopharma Common, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Statement-level metrics reflect company-reported GAAP or IFRS formats for the relevant filing period.